Proteomic Profiling of Bone Marrow Aspirates from Patients with Methotrexate- and Vincristine-Resistant B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis
Esli Janai Flores-Palma, Diana Laura Gonzalez-Tolentino, Sergio Encarnación-Guevara, Jeovanis Gil, Ramiro Alonso-Bastida, Angel Gabriel Martínez-Batallar, Mónica Virginia Saavedra-Herrera, Eloísa Ibarra-Sierra, Yazmín Gómez-Gómez, Berenice Illades-Aguiar, Olga Lilia Garibay-Cerdenares, Marco Antonio Leyva-Vázquez · 2026
Read Proteomic Profiling of Bone Marrow Aspirates from Patients with Methotrexate- and Vincristine-Resistant B-Cell Acute Lymphoblastic Leukemia: A Retrospective Analysis by Esli Janai Flores-Palma, Diana Laura Gonzalez-Tolentino, Sergio Encarnación-Guevara, Jeovanis Gil, Ramiro Alonso-Bastida, Angel Gabriel Martínez-Batallar, Mónica Virginia Saavedra-Herrera, Eloísa Ibarra-Sierra, Yazmín Gómez-Gómez, Berenice Illades-Aguiar, Olga Lilia Garibay-Cerdenares, Marco Antonio Leyva-Vázquez (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13516805.txt.
Description
Esli Janai Flores-Palma leads a twelve-author team profiling proteins in childhood leukaemia that resists first-line drugs, in a 2026 retrospective analysis. B-cell acute lymphoblastic leukaemia is the commonest childhood cancer, and ten to twenty percent of patients relapse when induction drugs fail. The team ran mass spectrometry on bone marrow samples taken before treatment, comparing children who responded to vincristine and methotrexate with those who did not.
Nonresponders carried a distinct protein pattern before any drug was given. The shifts centred on the cell's skeleton and its movement, on nucleic acid handling, DNA repair, and RNA processing. Two proteins, thymidine phosphorylase and gelsolin, stood out as consistently raised in nonresponders, patient by patient. Flores-Palma's team names them candidate warning markers of built-in resistance. Validation by other methods in bigger, independent groups must come before clinical use.
Catalog record
| CREATOR | Esli Janai Flores-Palma, Diana Laura Gonzalez-Tolentino, Sergio Encarnación-Guevara, Jeovanis Gil, Ramiro Alonso-Bastida, Angel Gabriel Martínez-Batallar, Mónica Virginia Saavedra-Herrera, Eloísa Ibarra-Sierra, Yazmín Gómez-Gómez, Berenice Illades-Aguiar, Olga Lilia Garibay-Cerdenares, Marco Antonio Leyva-Vázquez |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |